We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes

By LabMedica International staff writers
Posted on 14 Apr 2025

Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. More...

Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for surgical intervention. Complicating the situation, pancreatic tumors are made up of various subtypes of malignant cells, each of which responds differently to treatment. However, a newly developed technique can now identify and classify these cancer cell subtypes based on the sugars found on the surface of the cancer cells. These sugars, known as glycans, are involved in cell communication and recognition and serve as a cellular “signature,” with each subtype of pancreatic cancer cells having a unique glycan composition.

This innovative technique, known as multiplexed glycan immunofluorescence, was developed by researchers at the Van Andel Institute (Grand Rapids, MI, USA) in collaboration with other scientists, and has been detailed in the journal Science Advances. The method utilizes advanced software and imaging technology to precisely identify the mix of pancreatic cancer cell subtypes within a tumor. In the future, this approach may help in achieving earlier and more accurate diagnoses. The team initially identified glycan signatures by analyzing tumor tissue and then refined their technique to detect these glycans secreted into the blood by cancer cells.

This development is crucial, as blood tests are less invasive for patients, offering a quicker, more affordable, and non-invasive alternative to surgery. While the method is not yet available for use in clinical settings, the researchers are optimistic that it could become a standard diagnostic tool for pancreatic cancer in the coming years. In the meantime, the team continues to validate their method and explore the possibility of detecting rarer cell types. Additionally, they are investigating whether this technique can be applied to better detect and characterize other gastrointestinal cancers.

“Our new method allows us to go one step beyond cancer diagnosis by revealing which subtypes of pancreatic cancer cells make up a tumor. The more we know about which cells are present, the better physicians can tailor treatments for each patient,” said Brian Haab, Ph.D., a VAI professor and corresponding author of the study.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
HbA1c Test
HbA1c Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.